Clinical trial
Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed…
NCT00381654 · AVEO Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00381654 |
|---|---|
| Title | Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies |
| Official title | A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies |
| Lead sponsor | AVEO Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumor |
| Intervention type | Drug |
| Interventions | AV-412 |
| Enrollment | 27 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Feb 1, 2010 |
| First posted | Sep 28, 2006 |
| Last update posted | Oct 4, 2011 |
| Countries | Argentina, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: